|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM142415251 |
| 003 |
DE-627 |
| 005 |
20231223024511.0 |
| 007 |
tu |
| 008 |
231223s2003 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed24n0475.xml
|
| 035 |
|
|
|a (DE-627)NLM142415251
|
| 035 |
|
|
|a (NLM)14499250
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Fleming, Sherry D
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a C5a causes limited, polymorphonuclear cell-independent, mesenteric ischemia/reperfusion-induced injury
|
| 264 |
|
1 |
|c 2003
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 30.10.2003
|
| 500 |
|
|
|a Date Revised 08.11.2019
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a C5 is critical in the development of local mucosal damage and inflammation as well as in the development of remote organ injury after mesenteric ischemia/reperfusion (IR). To define the role of C5a in tissue injury, we treated wild-type mice with a cyclic hexapeptide C5a receptor antagonist (C5aRa) and administered recombinant C5a to C5 deficient (C5(-/-)) mice subjected to mesenteric IR. We demonstrate that at 2-h postreperfusion, C5a administered to C5-/- mice during IR induces limited intestinal mucosal injury but failed to cause remote lung injury despite the fact that it upregulated adhesion molecule expression. C5aRa treatment of C5+/+ mice undergoing IR limited local injury and prevented distant organ injury. We conclude that although C5a can trigger certain components of the IR induced injury, other mediators such as C5b-9 and local factors are needed for the complete expression of IR tissue damage
|
| 650 |
|
4 |
|a Comparative Study
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, U.S. Gov't, Non-P.H.S.
|
| 650 |
|
4 |
|a Research Support, U.S. Gov't, P.H.S.
|
| 650 |
|
7 |
|a Antigens, CD
|2 NLM
|
| 650 |
|
7 |
|a Complement C5
|2 NLM
|
| 650 |
|
7 |
|a Complement Membrane Attack Complex
|2 NLM
|
| 650 |
|
7 |
|a Eicosanoids
|2 NLM
|
| 650 |
|
7 |
|a Receptor, Anaphylatoxin C5a
|2 NLM
|
| 650 |
|
7 |
|a Receptors, Complement
|2 NLM
|
| 650 |
|
7 |
|a Recombinant Proteins
|2 NLM
|
| 650 |
|
7 |
|a Vascular Cell Adhesion Molecule-1
|2 NLM
|
| 650 |
|
7 |
|a Integrin alpha4
|2 NLM
|
| 650 |
|
7 |
|a 143198-26-9
|2 NLM
|
| 650 |
|
7 |
|a Complement C5a
|2 NLM
|
| 650 |
|
7 |
|a 80295-54-1
|2 NLM
|
| 700 |
1 |
|
|a Mastellos, Dimitrios
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Karpel-Massler, Georg
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Shea-Donohue, Terez
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lambris, John D
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Tsokos, George C
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 108(2003), 3 vom: 19. Sept., Seite 263-73
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:108
|g year:2003
|g number:3
|g day:19
|g month:09
|g pages:263-73
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 108
|j 2003
|e 3
|b 19
|c 09
|h 263-73
|